Bookmarks
Comparability and Relative Effectiveness of Osteoporosis Treatment Groups in European Clinical Practice
Safe People
Amgen Ltd
Commercial
James O'Kelly - Chief Investigator - Amgen LtdEng Hooi Tan - Corresponding Applicant - University of OxfordClement Erhard - Collaborator - Amgen LtdDaniel Prieto-Alhambra - Collaborator - University of OxfordJoe Maskell - Collaborator - Amgen LtdVictoria Y Strauss - Collaborator - University of Oxford
Safe Projects
CPRD882
Osteoporosis weakens bones, making them more likely to break (fracture). Treatment options for osteoporosis have been effective to reduce fracture risk but it is unknown which type of treatment is better. There may be differences in characteristics (age, medical condition, fracture history etc) amongst patients receiving different treatments. The differences in patient characteristics that may affect the type of treatment they receive and also their risk of fracture are known as confounders. These confounders need to be accounted for to allow the treatment groups to be comparable.
Objectives
15/01/2021
Safe Data
HES Admitted Patient Care
ONS Death Registration Data
Patient Level Index of Multiple Deprivation
Safe Setting
Release